Folyóiratcikkek tallózása szerző szerint "Canete A"

A találatok rendezése: Rendezés: Találatok:

  • Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. 
    Ladenstein R; Potschger U; Pearson AD; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami, Miklós; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D; SIOP Europe Neuroblastoma Group (SIOPEN) (2017)
    BACKGROUND: High-dose chemotherapy with haemopoietic stem-cell rescue improves event-free survival in patients with high-risk neuroblastoma; however, which regimen has the greatest patient benefit has not been established. ...
  • The state of research into children with cancer across Europe : New policies for a new decade 
    Pritchard-Jones K; Lewison G; Camporesi S; Vassal G; Ladenstein R; Benoit Y; Predojevic JS; Sterba J; Stary J; Eckschlager T; Schroeder H; Doz F; Creutzig U; Klingebiel T; Kosmidis HV; Garami, Miklós; Pieters R; O'Meara A; Dini G; Riccardi R; Rascon J; Rageliene L; Calvagna V; Czauderna P; Kowalczyk JR; Gil-da-Costa MJ; Norton L; Pereira F; Janic D; Puskacova J; Jazbec J; Canete A; Hjorth L; Ljungman G; Kutluk T; Morland B; Stevens M; Walker D; Sullivan R (2011)
    Overcoming childhood cancers is critically dependent on the state of research. Understanding how, with whom and what the research community is doing with childhood cancers is essential for ensuring the evidence-based ...